REG - Sareum Holdings PLC - Notice of AGM, Annual Report and Accounts

Sareum HoldingsAnnouncement

21/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231121:nRSU0551Ua&default-theme=true

RNS Number : 0551U  Sareum Holdings PLC  21 November 2023

Sareum Holdings PLC

("Sareum" or the "Company")

 

Notice of AGM, Annual Report and Accounts

 

Cambridge, UK, 21 November 2023 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, today announces that the Company's Annual
General Meeting ("AGM") will be held at 10.00am on 14 December 2023 at 85
Gresham Street, London EC2V 7NQ.

 

In order to allow shareholders to follow the proceedings of the AGM without
attending in person, the Company will provide access online via the Investor
Meet Company ("IMC") platform. Shareholders who wish to follow the AGM online
should register for the event in advance by using the following link:
www.investormeetcompany.com/sareum-holdings-plc/register-investor.

 

Shareholders are invited to submit questions for the Board to consider in the
Q&A session to be held immediately after the AGM. Questions can be pre
submitted via the IMC Platform up until 9.00am the day before the meeting and
can be submitted at any time during the AGM itself. Shareholders are reminded
that following the AGM online will not constitute attendance at the AGM and
therefore will not be able to vote on the day.

 

Shareholders intending to vote should do so via the shareholder portal at
www.signalshares.com (http://www.signalshares.com) where details of the
procedure are shown. Alternatively, shareholders may request a paper form of
proxy from our registrars, Link Group.

 

The notice of AGM, along with a copy of the Company's annual report and
accounts for the year ended 30 June 2023, will be posted today to those
shareholders who requested a hard copy. A copy of both documents will also be
available on the Company's website: www.sareum.com (http://www.sareum.com)

 

-Ends-

 

For further information, please contact:

 

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Lauren Williams, Head of Investor Relations         ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 ICR Consilium (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

 

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

 

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

 

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

 

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABMBMTMTITTAJ